当前位置: X-MOL 学术Cell Prolif. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Peptide‐based therapeutic cancer vaccine: Current trends in clinical application
Cell Proliferation ( IF 5.9 ) Pub Date : 2021-03-22 , DOI: 10.1111/cpr.13025
Wensi Liu 1, 2 , Haichao Tang 1, 2 , Luanfeng Li 1, 2 , Xiangyi Wang 1, 2 , Zhaojin Yu 1, 2 , Jianping Li 1, 3, 4
Affiliation  

The peptide‐based therapeutic cancer vaccines have attracted enormous attention in recent years as one of the effective treatments of tumour immunotherapy. Most of peptide‐based vaccines are based on epitope peptides stimulating CD8+ T cells or CD4+ T helper cells to target tumour‐associated antigens (TAAs) or tumour‐specific antigens (TSAs). Some adjuvants and nanomaterials have been exploited to optimize the efficiency of immune response of the epitope peptide to improve its clinical application. At present, numerous peptide‐based therapeutic cancer vaccines have been developed and achieved significant clinical benefits. Similarly, the combination of peptide‐based vaccines and other therapies has demonstrated a superior efficacy in improving anti‐cancer activity. We delve deeper into the choices of targets, design and screening of epitope peptides, clinical efficacy and adverse events of peptide‐based vaccines, and strategies combination of peptide‐based therapeutic cancer vaccines and other therapies. The review will provide a detailed overview and basis for future clinical application of peptide‐based therapeutic cancer vaccines.

中文翻译:

基于肽的治疗性癌症疫苗:临床应用的当前趋势

作为治疗肿瘤免疫疗法的有效方法之一,基于肽的治疗性癌症疫苗近年来引起了极大的关注。大多数基于肽的疫苗基于刺激CD8 + T细胞或CD4 +的表位肽T辅助细胞靶向肿瘤相关抗原(TAA)或肿瘤特异性抗原(TSA)。已经开发了一些佐剂和纳米材料来优化表位肽的免疫应答效率以改善其临床应用。目前,已开发出许多基于肽的治疗性癌症疫苗,并已取得了显着的临床益处。同样,基于肽的疫苗和其他疗法的组合在改善抗癌活性方面显示出卓越的功效。我们深入研究了靶标的选择,表位肽的设计和筛选,基于肽的疫苗的临床疗效和不良事件,以及基于肽的治疗性癌症疫苗和其他疗法的策略组合。
更新日期:2021-05-02
down
wechat
bug